reports
Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort o...
Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangliosidosis On-track to report topline results from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the first patient has been dosed in the high-dose cohort of the Phase 1/2 (“Stage 1”) study for Type I (infant...
Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D.,...
Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor A pioneering researcher, Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapyDr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of the top 20 translational researchers by Nature Biotechnology NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to...
Sio Gene Therapies Announces Corporate Updates and Financial Results f...
Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020 Continued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseasesCompleted rebranding to Sio Gene Therapies as part of corporate transformation aligning corporate structure and governance with current and future business activityCompany had $63.2 million of cash and cash equivalents as of September 30, 2020, with sufficient cash runway into Q4 2021 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 13,...
Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
Axovant Gene Therapies Announces Name Change to Sio Gene Therapies Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicinesCompany’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, today announced it will change its name to Sio Gene Therapies, Inc., effective ...
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 ...
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseasesRepresents Axovant’s second IND clearance for a gene therapy program in the last 12 months NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold and cleared the Investigati...
Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During V...
Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020 Patient-level data in cohort 2 of SUNRISE-PD study demonstrates consistent, clinically meaningful outcomes and evidence of dose responseDelays in manufacturing process expected to postpone the start of enrollment in randomized, controlled studyVirtual R&D Day webcast on October 30th at 11:30 AM Eastern time NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today an...
Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on ...
Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020 Agenda to feature presentations from leading clinical researchers in Parkinson’s disease and the Michael J. Fox FoundationIndividual patient-level data from Cohort 2 of the Phase 2 SUNRISE-PD study to be shared NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host a virtual R&D Day on Friday, October 30, 2020 at 11:30 AM Eastern time, to discuss the Company’s AXO-Le...
Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and P...
Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences" - Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists NEW YORK and BASEL, Switzerland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the company will provide a corporate overview and participate in 1:1 meetings at upcoming virtual investor and patient confe...
Axovant Announces Corporate Updates and Financial Results for First Fi...
Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2020 Data readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PDCompany had $55.5 million of cash and cash equivalents as of June 30, 2020 NEW YORK and BASEL, Switzerland, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, today provided financial results f...
Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedi...
Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, announced today that its subsidiary has signed a three-year Clinical Supply Agreement (“CSA”) with Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group. The CSA builds on the worldwide license agreement signed between the two companies in June 2018 for the Park...
Axovant Announces Year-End Financial Results and Expected Key Clinical...
Axovant Announces Year-End Financial Results and Expected Key Clinical Milestones in Q4 2020 Completed enrollment of cohort 2 of SUNRISE-PD Phase 2 study of AXO-Lenti-PD in Parkinson’s disease, with data from this cohort expected in Q4 2020Completed enrollment of low-dose cohort of Phase 1/2 clinical study of AXO-AAV-GM1 for GM1 gangliosidosis, with data from this cohort expected in Q4 2020Cash position of $80.8 million as of March 31, 2020 and expected runway into the second calendar quarter of 2021 NEW YORK and BASEL, Switzerland, June 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therap...
Axovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of ...
Axovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I (Infantile Onset) Patients with GM1 Gangliosidosis - Six-month data from low-dose cohort expected in Q4 2020- IND amended to include Type I (infantile onset) patients and to evaluate a higher dose- Expect to initiate high-dose cohort in 2H 2020 NEW YORK and BASEL, Switzerland, June 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has ...
Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual...
Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference NEW YORK and BASEL, Switzerland, May 28, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that Parag Meswani, Pharm.D., SVP of Commercial Strategy and Operations, will present at the Jefferies Global Virtual Healthcare Conference. Presentation Details: Date: Thursday, June 4, 2020Time: 3:00 PM EDTWebcast link: A replay of the presentation will be available in the Eve...
Axovant Announces Upcoming Presentations at the Annual Meeting of the ...
Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy NEW YORK and BASEL, Switzerland, May 07, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced upcoming presentations regarding its investigational gene therapy programs, AXO-Lenti-PD and AXO-AAV-GM2 at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), held virtually on May 12th to May 15th, 2020. Oral Presentation Details: Oral ...
Axovant Announces Full Prepayment of Outstanding Loan from Hercules Ca...
Axovant Announces Full Prepayment of Outstanding Loan from Hercules Capital Company’s balance sheet is now free of debt NEW YORK and BASEL, Switzerland, April 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had prepaid in full its $15.7 million outstanding loan from Hercules Capital, Inc. together with interest, fees and other amounts due. Following the prepayment, the credit facility and loan agreement with Hercules Capital, Inc. was terminated, and all obligations,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.